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The development of breast implant-associated anaplastic large-cell lymphoma (ALCL) is a
rare phenomenon. A typical presentation is an effusion associated with a breast implant.
Less commonly, disease can be more advanced locoregionally or distantly. The optimal
treatment schema is a topic of debate: localized ALCL can potentially be cured with implant
removal alone, while other cases in the literature, including those that are more advanced,
have been treated with varying combinations of surgery, chemotherapy, and external beam
radiotherapy.This is a case report of breast implant ALCL with pathologically proven lymph
node involvement, the fifth such patient reported. Our patient experienced a favorable
outcome with radiation therapy and chemotherapy.
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INTRODUCTION
A 76-year-old Caucasian woman was found to have implant-
associated anaplastic lymphoma with pathologically proven nodal
involvement and was successfully treated by implant removal,
chemotherapy, and radiotherapy. She had gel breast implanta-
tion performed 20 years prior to presentation. These were later
replaced by saline implants. One year before presentation the
saline implants were leaked and replaced with gel implants. She
developed a recurrent fluid collection involving her right breast
(Figure 1). A drain was placed and yielded minimal output before
being removed 1 week later. Cytology of the fluid demonstrated
atypical appearing lymphocytes. The fluid later reaccumulated,
and right axillary lymphadenopathy was noted on physical exam
(largest node 5.1 cm on ultrasound). Core needle biopsy of the
node revealed rare atypical cells.
She underwent capsulectomy and right axillary nodal excisional
biopsy with bilateral implant removal in 2011. On histopathologic
analysis, anaplastic large-cell lymphoma (ALCL), anaplastic lym-
phoma kinase (ALK)-negative was demonstrated in the fibrous
capsule, cystic fluid, and axillary lymph nodes (Figures 2 and 3).
Imaging with CT and PET scans demonstrated residual right axil-
lary lymphadenopathy with FDG avidity, as illustrated in Figure 4.
Bone marrow analysis was performed and showed no evidence of
lymphoma involvement. The patient was staged as Ann Arbor
stage IIE. She was treated with six cycles of cyclophosphamide
750 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, and pred-
nisone. Prednisone required a dose reduction from 100 to 75 mg
after the first cycle to minimize hyperglycemia secondary to dia-
betes mellitus type II. Pegfilgrastim 6 mg was injected each cycle
for hematopoietic support. Ciprofloxacin 500 mg BID was used
daily for bacterial infection prophylaxis. After cycle 2, she began
to display adverse effects of nausea grade 2, oral mucositis grade
1, and dysgeusia grade 2 per National Cancer Institute Common
Terminology Criteria for Adverse Events grading scale version 4.03
(1). Tetrahydrocannabinol was administered for treatment of nau-
sea and anorexia. Weight loss of grade 1 occurred by the end of
therapy. Interval PET and CT imaging were performed after cycle
2, demonstrating metabolic activity of SUV 0.88 in the right axil-
lary lymph nodes, a partial response. Repeat PET imaging was
performed after cycle 4 of chemotherapy, confirming complete
response to treatment.
Adjuvant radiation therapy was then delivered to the right
breast, axilla, and right supraclavicular nodes to 30.6 Gy in 1.80 Gy
fractions, finishing in January of 2012. A monoisocentric tech-
nique was used with breast tangents matched to a field covering
the supraclavicular nodes and high axilla. The axilla levels 1–3 were
contoured and a lightly weighted posterior axillary field was used
to bring the volume up to the prescription dose (Figure 5). With
therapy, the patient experienced grade 1 dermatitis manifested
as faint erythema within the treatment field. Two-year follow-up
with PET imaging and clinical evaluation showed no evidence of
disease. The patient wished to have breast augmentation again.
She underwent silicone gel implant placement bilaterally and has
been followed for an additional year without evidence of disease.
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FIGURE 1 | Firmness and marked increase in size of the right breast as
seen on presenting physical examination.
FIGURE 2 | Effusion fluid (seroma). Anaplastic large cells present in the
effusion surrounding the breast implant. Anaplastic large cells also involve
the breast implant capsule (not shown). Immunohistochemical staining
shows anaplastic large-cell lymphoma T-cell type.
BACKGROUND
Primary breast lymphomas represent about 0.1–0.5% of total
breast tumors, and approximately 3% of non-Hodgkin lym-
phomas of extranodal sites (2). Tumors of ALCL histology rep-
resent 2% of adult non-Hodgkin lymphomas and are the second
most common peripheral T cell lymphoma (3, 4). The entity of
breast implant-associated ALCL was first described by Keech and
Creech (5) in 1997, and currently at least 60 cases have been
described in the literature (6). A study in the Netherlands esti-
mated that the incidence of breast implant-associated ALCL is 1
out of 500,000 per woman with prostheses per year, using a case–
control model with breast lymphomas other than ALCL as the
control (7). However, there has been controversy regarding the
FIGURE 3 | Axillary lymph node. Axillary lymph node of the same patient
shows large atypical cells involving the sinusoidal and lymphatic space,
consistent with anaplastic large cells involving the lymph node.
level of risk associated with breast prosthesis implantation (8).
The FDA reports that 5–10 million women have undergone breast
implantation, leading to a possible estimation of breast-associated
ALCL incidence of 1:80,000 to 1:170,000 given the 60 reported
cases thus far (9).
Morphologically, ALCL is composed of large blastic cells with
pleomorphic, often horseshoe-shaped or multiple nuclei. Growth
is in a cohesive pattern often involving lymph node sinuses with a
variable composition of granulocytes and macrophages. In breast-
associated and cutaneous ALCL, the cells are CD30 positive on
cytogenetic studies and negative for ALK (10). In contrast, sys-
temic ALCL is characterized by positive ALK (11). Those who
present with a mass rather than an effusion have a higher risk
of failure or relapse (12). Various treatment regimens have been
employed including surgery (implant removal) followed by obser-
vation, chemotherapy alone, chemotherapy and radiation, and
radiation alone. Patients who present with disease limited to an
effusion surrounding the fibrous capsule surrounding the implant
have been shown to have a favorable outcome with observation;
however, there are rare cases of advanced and treatment-resistant
disease leading to fatality (13). The ideal treatment schema is yet
to be elucidated.
We report a locally advanced case of breast implant-associated
ALCL at our institution. Pathologic axillary nodal involvement
by breast implant-associated ALCL is rare: only four cases of
pathologically confirmed disease of the axillary nodes have been
described. Of the 60 cases reported, workup for axillary nodal
involvement was carried out in 29, 10 of which were found to have
clinical evidence of axillary lymphadenopathy. Four of these were
confirmed pathologically (6); our patient represents the fifth.
DISCUSSION
Treatment methods in breast implant-associated ALCL have
included surgery, radiation therapy, chemotherapy, their vari-
ous combinations, and observation. Overall survival is typically
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FIGURE 4 | Right axillary lymphadenopathy demonstrated on axial and coronal PET scan images with abnormal FDG avidity (A,B) and coronal
CT images with contrast (C,D).
FIGURE 5 | Coronal CT slice of treatment plan showing isodose lines and contoured axillary nodal volume.
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favorable, and only three patients have been reported to die of dis-
ease. ALCL can also present in a systemic or cutaneous manner.
Systemic disease is typically more aggressive; those with cuta-
neous lymphomas carry a more favorable prognosis and negative
ALK, similar to breast ALCL (14). On long-term follow-up of
the 60 patients reported by Miranda et al., patients who were
found to have disease confined to the fibrous capsule experienced
improved complete response, overall survival, and progression-
free survival. Those treated with chemotherapy alone did not
experience improved outcome compared to those treated with
either watchful waiting or radiotherapy alone. The four patients
who received radiotherapy alone are free from recurrence (6).
Patients who present with effusion confined disease have had
long-term relapse free intervals with observation alone. Those
with a mass show a more aggressive prognosis, and may achieve a
greater benefit with combined modality therapy with chemother-
apy and radiation. Implant removal in ALCL is recommended:
in one review, three of four patients without implant removal
relapsed, all of whom responded to salvage therapy (12). More
aggressive tumors may arise in those patients with prior breast
cancer (15).
CONCLUDING REMARKS
For the advanced presentation of axillary nodal involvement in our
patient, we obtained a favorable outcome with combined modality
treatment with radiation therapy and chemotherapy. Our patient
chose to undergo placement of new implants after her treatment.
It was discussed with the patient that the risks of implant replace-
ment after treatment are unknown in this setting. She chose to
proceed and has had no adverse consequence to date. Finally,
this clinical scenario highlights the importance of regional nodal
evaluation in patients with breast implant ALCL.
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